Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Enrollment
- 430
- Locations
- 1
- Primary Endpoint
- TLF
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Drug-coated balloon is being used more and more widely for the advantage of intervention without implantation.
But the balloon needs to be released long enough to be effective. Prolonged balloon dilation resulting in the cessation of blood flow in the distal vessels, especially large vessels, may result in severe ischemia in the patient.
RIPC can enhance patients' tolerance to ischemic events, so we believe that RIPC application before the use of drug balloon for PCI can improve patients' ischemic symptoms, thus increasing the release time of drug balloon and improving the effect.
Detailed Description
Some patients receiving PCI cannot tolerate the symptoms of myocardial ischemia caused by the release of the drug balloon for a long time and even lead to the occurrence of adverse events.RIPC was found to improve tolerance to myocardial ischemia in patients. At the same time, it can open collateral circulation and improve the tolerance of myocardial ischemia in patients.Therefore, this study designed a parallel control group. The experimental group was treated with RIPC before PCI, while the control group was not treated before PCI. The operator does not know whether the patient has undergone RIPC or not, and the operator decides the time of drug balloon release according to the symptoms of the patient during the operation.Angiography was performed at 6 months, and QCA was used to determine late lumen loss at 1 year.The 1-year incidence of target lesion failure events was assessed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diameter stenosis\>=50% by visual estimation intend to undergo drug-coated balloon implantation
- •Target vessel diameter\> 2.5mm
Exclusion Criteria
- •Chronic Total Obstructive lesion
- •Diagnose patients with acute myocardial infarction \<24 hours
- •Can't tolerate or not suitable for RIPC
- •Severe hepatic and renal insufficiency
- •Expected survival \<1 year
- •Severe calcification needing rotational atherectomy
- •Intolerable to dual antiplatelet therapy
Outcomes
Primary Outcomes
TLF
Time Frame: 12 months
TLF, a composite of cardiac death, target vessel-related myocardial infarction (MI; not clearly attributed to a nontarget vessel and excluding periprocedural MI), or clinically indicated target lesion revascularization (TLR)
Secondary Outcomes
- DCB expansion time(less than 120 seconds (On the 1 day of PCI))
- Late lumen loss of target vessel（mm）(6 months)